Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > UTA cancer researcher to lead national organization
View:
Post by Eoganacht on Sep 21, 2024 6:02pm

UTA cancer researcher to lead national organization

Sherri McFarland named President of American Society of Photobiology

Friday, Sep 20, 2024 • Katherine Egan Bennett

Sherri McFarland

Sherri McFarland, a professor of chemistry and biochemistry at UTA, is the new president of the American Society for Photobiology

University of Texas at Arlington cancer researcher Sherri McFarland has been elected president of the American Society for Photobiology (ASP), a national scientific organization dedicated promoting research related to the effects of light on human health and the broader natural world.
 
“I am honored to be elected president of this great organization and hope to help it thrive for years to come,” said Dr. McFarland, a professor of chemistry and biochemistry at UTA. “As president, I am committed to advancing our mission of promoting research in photobiology, integrating different photobiology disciplines, disseminating photobiology knowledge, mentoring the next generation of photobiologists and providing information on photobiological aspects of national and international issues.”
 
McFarland is a nationally recognized researcher for her work developing a cancer medication that uses light to target and destroy cancer cells in a process known as photodynamic therapy. This technology is currently being used to treat bladder cancer patients in clinical trials. She recently received another grant from the National Science Foundation to study the ways in which this special drug interacts with light to destroy some of the most aggressive cancers.
 
In addition, McFarland has received numerous patents for her research in photomedicine and co-founded a company that has commercialized another light-based therapy. In 2024, she was named a senior member of the National Academy of Inventors for producing technologies that aspire to have a real impact on the welfare of society.
 
“A lot of people don’t realize there are other treatments for cancer, such as light-based therapies. In fact, even some oncologists don’t know much about them, focusing instead on chemotherapy, radiation, immunotherapy or surgery,” said McFarland. “That’s why the work at the ASP is so important. As a society, we’re devoted to disseminating photobiology knowledge and making societal impact through advances in the photobiological sciences.”
 
In McFarland’s specific area of research, this means researching and promoting the benefits of photodynamic treatments so more patients and their loved ones can potentially be helped.
 
“It has been an honor to associate with Sherri over the years and see the influence she provides as an ambassador for the photobiological sciences,” said Shiyong Wu, outgoing president of the ASP. “Her dynamic leadership and drive to get things done will be a major contributor in ASP’s future success. I look forward to seeing what our organization will accomplish in the coming years under her leadership.”
Comment by Legit62 on Sep 21, 2024 8:24pm
It would be nice to get our name out there to the cancer community. need some more exposurer
Comment by Yajne on Sep 21, 2024 8:45pm
Great find Eogan, thanks for posting. Hopefully as President of the society, Dr McFarland will be successful in improving exposure for light-based therapies, which is one of her stated goals: “A lot of people don’t realize there are other treatments for cancer, such as light-based therapies. In fact, even some oncologists don’t know much about them, focusing instead on chemotherapy, radiation ...more  
Comment by gonefishing2022 on Sep 22, 2024 4:17pm
This is very Good News Helps me have even more confidence 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250